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(See the Editorial Commentary by Qazi, Fox, and Thea on pages 1225–7.)
Background. There are concerns that the evidence from studies showing noninferiority of oral amoxicillin to
benzyl penicillin for severe pneumonia may not be generalizable to high-mortality settings.
Methods. An open-label, multicenter, randomized controlled noninferiority trial was conducted at 6 Kenyan
hospitals. Eligible children aged 2–59 months were randomized to receive amoxicillin or benzyl penicillin and
followed up for the primary outcome of treatment failure at 48 hours. A noninferiority margin of risk difference
between amoxicillin and benzyl penicillin groups was prespeciﬁed at 7%.
Results. We recruited 527 children, including 302 (57.3%) with comorbidity. Treatment failure was observed
in 20 of 260 (7.7%) and 21 of 261 (8.0%) of patients in the amoxicillin and benzyl penicillin arms, respectively
(risk difference, −0.3% [95% conﬁdence interval, −5.0% to 4.3%]) in per-protocol analyses. These ﬁndings were
supported by the results of intention-to-treat analyses. Treatment failure by day 5 postenrollment was 11.4% and
11.0% and rising to 13.5% and 16.8% by day 14 in the amoxicillin vs benzyl penicillin groups, respectively. The
most frequent cause of cumulative treatment failure at day 14 was clinical deterioration within 48 hours of en-
rollment (33/59 [55.9%]). Four patients died (overall mortality 0.8%) during the study, 3 of whom were allocated
to the benzyl penicillin group. The presence of wheeze was independently associated with less frequent treatment
failure.
Conclusions. Our ﬁndings conﬁrm noninferiority of amoxicillin to benzyl penicillin, provide estimates
of risk of treatment failure in Kenya, and offer important additional evidence for policy making in sub-Saharan
Africa.
Clinical Trial Registration. NCT01399723.
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Almost half of all deaths due to childhood pneumonia
occur in sub-Saharan Africa [1].World Health Organi-
zation (WHO) recommendations for case management
of pneumonia in children aged 2–59 months have been
credited with contributing to substantial reductions in
mortality [2]. For >2 decades, these guidelines have rec-
ommended classiﬁcation into 4 classes of severity based on
clinical signs at initial presentation, with inpatient man-
agement reserved for the severe categories (Figure 1) [3].
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Recently, however, WHO undertook a major revision of these
guidelines. Children with lower chest wall indrawing are now to
be treated with outpatient oral amoxicillin, replacing inpatient
benzyl penicillin [4]. Supporting evidence came from large mul-
ticenter studies including >3000 children, predominantly from
Asian countries [5, 6]. The WHO panel utilizing the Grading of
Recommendations Assessment Development and Evaluation
process [7] was moderately conﬁdent in these effect estimates
and provided a strong recommendation in favor of this policy
shift [8].
The same evidence was reviewed and discussed in Kenya in
2010 as part of a national guideline development exercise. In
this context-speciﬁc decision-making process, the supporting ev-
idence was also graded as of moderate quality, with downgrading
for indirectness given the small number of African children in-
volved in the trials. A panel of >70 individuals from clinical,
policy, and academic backgrounds who participated in this
national process had concerns over the generalizability of the
results drawn from predominantly Asian study subjects to
populations in sub-Saharan Africa in whom mortality may be
higher [9]. On this background, the Kenyan group declined to
adopt outpatient oral amoxicillin to replace injectable benzyl
penicillin [10].
Prompted by this uncertainty, we sought to compare the
2 antibiotics in a population of Kenyan children. Of
speciﬁc interest, this trial provides the ﬁrst data on clinical
outcomes of children treated for severe pneumonia in an
African setting where comorbid conditions such as malaria,
diarrhea, and malnutrition are common and was conducted
after introduction of the routine childhood Haemophilus
inﬂuenzae type b (Hib) and pneumococcal vaccines in
Kenya.
METHODS
Participants
We conducted an open-label, pragmatic, randomized controlled
noninferiority trial. Children aged 2–59 months with severe
pneumonia as deﬁned in the 2005 WHO guidelines were re-
cruited from 6 public hospitals across Kenya. Three of the sites
are located in the central region of Kenya at elevations ranging
from 1350 m to 1700 m above sea level. The other 3 hospitals
are located in western Kenya around the Lake Victoria basin
where malaria is endemic (1100 m–1300 m above sea level).
All 6 facilities offer both primary care and referral services,
with pediatric inpatient departments reporting 2500–4500
annual pediatric admissions. Patient screening and enrollment
was conducted by trained study clinicians under supervision of
the hospital pediatricians who were also the site principal
investigators.
Eligibility Criteria
To mimic scenarios encountered in actual practice, we enrolled
children with common comorbidities including malaria, diar-
rhea, wheeze, and a single convulsion in the presence of fever.
As some form of treatment is common prior to consulting a
health professional, children with a recent history of treatment
with unknown oral antibiotics or those who had received <48
hours of amoxicillin were enrolled. Although enrolling children
with comorbidities or oral pretreatment would potentially bias
the results of the trial toward equivalence, we considered the
value of gaining data on the population who would actually be-
come the subject of future guidelines of overriding interest. To
minimize this bias, we ensured prompt and adequate manage-
ment of comorbidities. Children with primary diagnoses that
Figure 1. Kenyan Ministry of Health classiﬁcation of pneumonia for children aged 2–59 months with cough and/or difﬁculty breathing (without stridor,
severe malnutrition, or signs of meningitis). Abbreviation: RR, respiratory rate.
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would ordinarily preclude treatment with benzyl penicillin
monotherapy were excluded (Supplementary Figure 1).
All children were assessed for the presence of wheeze. Where
present, up to 3 doses of inhaled salbutamol were administered
as bronchodilator therapy, each separated by 15-minute intervals,
at the end of which they were reassessed. Those in whom signs of
severe pneumonia subsided exited the study with inhaled broncho-
dilators and corticosteroids, in linewith recommended practice [3].
Study Oversight
The Kenya Medical Research Institute (KEMRI) National Eth-
ical Review Committee (ERC), Kenya National Pharmacy and
Poisons Board, and University of Oxford Tropical Research
Committee approved the trial protocol. Written informed con-
sent was sought from accompanying legal guardians in a locally
appropriate language prior to enrollment. All serious adverse
events were reported to the KEMRI ERC and the data and safety
monitoring board (DSMB). One planned interim analysis was
conducted upon recruitment of approximately half of the
total sample size. Using the Haybittle–Peto adjustment for mul-
tiple testing, recruitment was to be halted if the P value from a
test of difference between the 2 groups was ≤.001 [11]. Upon
reviewing the report, the DSMB expressed satisfaction with
the ﬁndings and recommended continuation of recruitment
with no amendments to the protocol. Independent monitoring
was provided by the Clinical Trials Facility of the KEMRI–
Wellcome Trust Research Programme, Kiliﬁ, Kenya. The trial
is registered with ClinicalTrials.gov (NCT01399723).
Interventions
Eligible children were randomized to oral amoxicillin at the
WHO-recommended dose of 40–45 mg/kg twice daily or
intravenous/intramuscular benzyl penicillin at 50 000 IU/kg 4
times daily for a minimum of 48 hours. Additional supportive
care and laboratory and radiological investigations were per-
formed as determined by the clinical team managing the
ward patients. The clinical team was trained and advised to
strictly adhere to the study protocols and ensure that any chan-
ge of treatment was based on the study deﬁnitions of treatment
failure (Figure 2).
The study clinician conducted daily clinical reviews in consul-
tation with the hospital pediatrician. Study participants were
monitored for signs of clinical deterioration, which resulted in
prompt revision of treatment if detected. Follow-up data on inpa-
tient treatment failure and mortality continued until discharge
from hospital or day 5 postenrollment. At hospital discharge,
children in both study arms received adequate oral amoxicillin
to complete a total of 5 days of antibiotic treatment. Guardians
were counseled on correct administration of and adherence to
treatment prior to discharge. Mobile phone contacts collected
from the children’s parents or legal guardians were used to facil-
itate follow-up and capture information on any deaths and read-
missions both within and outside of the recruiting hospitals
through a telephone interview 2 weeks after enrollment. Caregiv-
ers of patients who we knew at discharge were not contactable by
telephone were requested to report to the hospital 2 weeks after
enrollment for a direct interview. Participants were compensated
for transport costs incurred to and from hospital for this visit.
Study Drugs
Trial lots of amoxicillin and benzyl penicillin were procured di-
rectly from the manufacturer with accompanying batch release
certiﬁcates. Quality of both study treatments was veriﬁed at a
local WHO-accredited laboratory.
Figure 2. Criteria for treatment failure. Abbreviation: bpm, breaths per minute.
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Outcomes
The primary outcome was treatment failure determined by the
study site clinician in discussion with the site principal investiga-
tor at 48 hours (2 full days after enrollment). Treatment failure
was deﬁned a priori as the development of any 1 of 5 prespeciﬁed
criteria (Figure 2). The secondary outcomes were cumulative
treatment failure 5 days after enrollment or upon hospital dis-
charge (whichever occurred sooner) and late treatment failure
at day 14, deﬁned as death or prolonged hospitalization, or hos-
pital readmission, or ongoing treatment with outpatient antibiot-
ics as determined through telephone or direct interview.
Statistical Analysis
Data on baseline characteristics were summarized by study arm.
Noninferiority between amoxicillin and benzyl penicillin was
deﬁned a priori as a risk difference of treatment failure and as-
sociated upper bound of the 95% conﬁdence interval (CI) of
<7%. This deﬁnition is comparable to those of previous studies
on childhood pneumonia [5, 6, 12–15]. The initial sample size
estimate of 576 children (288 per group) would provide 80%
power to detect noninferiority of amoxicillin against benzyl
penicillin within a margin of 7% at a 1-sided level of signiﬁcance
of 0.025, assuming a prevalence of treatment failure of 10% at 48
hours derived from a preintervention pilot phase of the study.
We undertook both intention-to-treat and per-protocol analy-
ses for the primary outcome.
We also explored independent risk factors for treatment
failure at 48 hours using a predictive logistic regression model.
Age, sex, and treatment group were included as a priori co-
variates. Univariate associations were tested for other potential
Figure 3. Screening allocation and follow-up of study participants.
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predictors of treatment failure. An inclusion cutoff of P < .1 was
applied to select covariates for inclusion in the ﬁnal model. All
analyses were conducted using Stata version 12.1 (StataCorp,
College Station, Texas).
Randomization
Computer-generated random sequences were created in blocks
of randomly varying sizes of 6–10, stratiﬁed by study site at the
KEMRI–Wellcome Trust Research Programme by an individual
independent of the investigators. Treatment allocations were
stored in sealed opaque envelopes distributed to the study
sites in complete blocks. Envelopes were issued to recruited par-
ticipants in order of enrollment. Due to the nature of the inter-
vention (injectable vs orally administered treatments), blinding
was not achieved. However, envelopes containing the assigned
treatment were only opened by the recruiting clinician after a
potential study patient was determined to have fully satisﬁed el-
igibility criteria ensuring allocation concealment. A screening
log was maintained to show corresponding accountability for
all opened allocation envelopes.
RESULTS
The trial was preceded by a pilot phase during which we recruited
208 children, in whom we observed a failure rate of 10.1% (95%
CI, 6.4–15.0) and 2 deaths. Characteristics of the children recruit-
ed in the pilot phase were similar to those in the trial.
During the intervention phase of the study, 527 were recruited
from 12 September 2011 to 15 August 2013. A total of 263 chil-
dren were randomized to receive amoxicillin whereas 264 received
benzyl penicillin. One patient in the benzyl penicillin group was
lost to follow-up before assessment for the primary outcome at 48
hours (Figure 3). Recruitment was adversely affected by several
unpredictable nationwide health worker strikes during the study
period. At one hospital, recruitment stopped after the site clini-
cian resigned from his position (8 months before the end of the
recruitment). Faced with uncertainty regarding the expected end
of the trial and a limited budget to prolong recruitment indeﬁnite-
ly, we decided to base the end of the trial on a ﬁxed date rather
than achieving the target sample size. No data analysis preceded
study termination. Thus, we concluded recruitment with a sample
size of 527 (49 patients below the original target).
Protocol violations were observed in 5 patients. Two patients
received inadequate doses of study drug, 1 patient missed 2
doses of study drug, treatment for 1 patient was changed in
the absence of any criteria for treatment failure, and 1 patient
was enrolled despite having been treated with oral amoxicillin
for >48 hours prior to admission. Data from these patients
were excluded from per-protocol analyses.
Comorbidities including malaria (conﬁrmed through mi-
croscopy), acute diarrheal illness, wheeze not responsive to
initial therapy, anemia, and moderate acute malnutrition were
present in 302 of 527 (57.3%) of study patients, rates of comor-
bidity consistent with previous reports in similar populations
[16, 17]. Baseline characteristics for recruited children were
comparable between the treatment groups (Table 1).
Of 11 patients with oxygen saturation recordings of 85%–
90%, treatment failure was observed in 1 patient (9.1%). This
ﬁnding was not statistically different from the risk of treatment
failure among children with oxygen saturations ≥90% (P = .87).
Main Outcomes
The risk of treatment failure was 7.7% in the amoxicillin arm and
8.0% in the benzyl penicillin arm at 48 hours in per-protocol
analyses (risk difference, −0.3% [95% CI, −5.0% to 4.3%]), indi-
cating noninferiority within the prespeciﬁed margin of 7% at 48
hours (Figure 4). Similar results were obtained in intention-to-
treat analyses. The risk difference of treatment failure between
the 2 treatment arms at all follow-up time-points was <7%:
−0.3% at 48 hours, 0.4% at day 5, and 3.3% at day 14 (Table 2).
Table 1. Baseline Characteristics of Recruited Children
Patient Characteristic Penicillin Amoxicillin
Age, mo, median (IQR) 13 (7–24) 14 (7–25)
Female sex 106/264 (40.2) 120/263 (45.6)
History of cough 263/264 (99.6) 262/263 (99.6)
History of fever 240/264 (90.9) 236/263 (89.7)
History of diarrhea 62/264 (23.5) 56/263 (21.3)
Recent antibiotic treatment 103/236 (43.6) 101/238 (42.4)
Received pneumococcal
and Hib vaccines, ≥1 dose
184/245 (75.1) 183/245 (74.7)
Temperature, °C, median
(IQR)
37.8 (37.3–38.5) 38.1 (37.5–38.8)
Oxygen saturation, %,
median (IQR)
94 (92–96) 95 (93–97)
WHZ < −2 SD below
median reference value
24/264 (9.0) 15/263 (5.7)
Any comorbidity 150/264 (56.8) 152/263 (57.8)
Wheeze 92/264 (34.9) 95/263 (36.1)
Slide-positive malaria 22/264 (8.3) 34/263 (12.9)
Pallor 20/264 (7.6) 19/263 (7.2)
Dehydration 20/264 (7.5) 11/263 (4.2)
Study site
Bungoma District Hospital 42/264 (15.9) 41/263 (15.6)
Embu Provincial General
Hospital
62/264 (23.1) 60/263 (22.8)
Kerugoya District Hospital 60/264 (22.7) 59/263 (22.4)
Kisumu District Hospital 37/264 (14.0) 36/263 (13.7)
Mbagathi District Hospital 39/264 (14.8) 41/263 (15.6)
New Nyanza Provincial
General Hospital
25/264 (9.5) 26/263 (9.9)
Data are presented as proportion (%) unless otherwise indicated.
Abbreviations: Hib, Haemophilus influenzae type b; IQR, interquartile range;
SD, standard deviation; WHZ, weight-for-height z score.
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Risk Factor Analysis
In univariate analyses, moderate acute malnutrition (weight-for-
height z score ≥−3 SD and <−2 SD vs ≥−2 SD) and history of
diarrhea were associated with increased odds of treatment failure
(odds ratio [OR], 2.91 [95% CI, 1.19–7.13]; P = .01 and OR, 2.4
[95% CI, 1.23–4.67]; P = .01, respectively). The presence of
wheeze was associated with reduced odds of treatment failure
(OR, 0.18 [95% CI, .06–.51]; P = .001). Treatment failure was
weakly associated with palmar pallor (OR, 2.35 [95% CI, .92–
6.0]; P = .07) and increasing length of illness in days (OR, 1.13
[95% CI, .98–1.30]; P = .08). Immunization status (pneumococ-
cal or Hib vaccines), laboratory diagnosis of malaria, and recent
antibiotic treatment were not associated with treatment failure.
A multivariable predictive model was used to determine inde-
pendent correlates of treatment failure adjusting for treatment
group, age, sex, length of illness, history of diarrhea, temperature,
wheeze at the time of recruitment, moderate acute malnutrition,
and a diagnosis of anemia. In the ﬁnal model, only presence of
wheeze was found to be associated with reduced risk of treatment
failure (OR, 0.21 [95% CI, .07–.63]; P = .005).
Causes of Treatment Failure
Approximately half (33/59) of the children who progressed, cu-
mulatively, to treatment failure were reported to have deteriorat-
ed, developing at least 1 of the signs of very severe pneumonia;
28 of these deteriorated within the ﬁrst 48 hours of admission.
In contrast, change of treatment by a clinician in the absence of
any of the trial-speciﬁed criteria for treatment failure was
observed more frequently as a late cause (>48 hours after admis-
sion) of treatment failure. Two patients (1 from each study
group) withdrew consent during the study (Table 3).
Late Treatment Failure and Mortality
Late treatment failure, assessed 14 days after enrollment, was
more frequent, although not statistically signiﬁcantly, in the
benzyl penicillin group (Table 2). However, the proportion of
children lost to follow-up by day 14 was slightly greater in the
amoxicillin group at 7.2% (19/263) vs 4.3% (13/264) (Figure 5).
Four study participants died (0.8%): 3 in the benzyl penicillin
group and 1 in the amoxicillin group. None of the deaths oc-
curred in the ﬁrst 48 hours of treatment. One death occurred
after hospital discharge, 12 days after recruitment. Cause of
death was ascribed to complications of acute diarrhea (n = 1),
congestive heart failure (n = 1), complications of chronic renal
failure (n = 1) unrecognized at enrollment, and possible intoxi-
cation related to ingestion of traditional herbal medicines
(n = 1). All deaths were reported to the DSMB and the
KEMRI ERC, who in all instances concluded that none of the
deaths was related to study drugs or procedures.
DISCUSSION
The results of this trial are consistent with ﬁndings of other
large multicenter studies [5, 6, 18] that informed a recent
evidence-driven review of the treatment guidelines for severe
pneumonia byWHO, recommending outpatient oral amoxicillin
Figure 4. Intention-to-treat and per-protocol analyses for treatment failure at 48 hours.
Table 2. Cumulative Treatment Failure at 48 Hours, Day 5, and Day 14
Treatment Group 48 h, PP, Proportion (%) 48 h, ITT, Proportion (%) Day 5, ITT, Proportion (%) Day 14, ITT, Proportion (%)
Amoxicillin 20/260 (7.7) 20/263 (7.6) 30/263 (11.4) 33/244 (13.5)
Penicillin 21/261 (8.0) 21/263 (8.0) 29/263 (11.0) 42/250 (16.8)
Risk difference, % (95% CI) −0.3 (−5.0 to 4.3) −0.4 (−5.0 to 4.2) 0.4 (−5.0 to 5.8) −3.3 (−10.0 to 3.0)
Abbreviations: CI, confidence interval; ITT, intention to treat; PP, per protocol.
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[8]. We have included our new data in a random-effects meta-
analysis with the 2 previous comparable trials [5, 6] (Supplemen-
tary Figure 2). The pooled risk difference for treatment failure
comparing amoxicillin vs benzyl penicillin is −0.6% (95% CI,
−2.4% to 1.2%; I2 = 0%, P = .77).
The risk of treatment failure in the trial was lower than the es-
timate obtained from the pilot from which the initial sample size
calculation was derived. This implies that the number of patients
recruited, although lower than the original target, may have been
adequate to achieve the study objectives. However, the overall risk
of treatment failure of almost 10% still represents a substantial
amount of suffering in both treatment groups. Thus, the need re-
mains for research to examine complementary interventions to
further reduce poor outcomes among children with severe
forms of pneumonia such as optimal feeding and ﬂuid regimens.
We excluded children with severe acute malnutrition and al-
ternative or additional severe illnesses according to Kenyan case
management guidelines [3] (which are broadly comparable with
WHO guidelines [4]). Exploratory analyses for factors associat-
ed with treatment failure were thus limited to milder levels of
risk. This may explain why factors that have traditionally been
associated with poor clinical outcomes were not found to be pre-
dictive of treatment failure in our study. Many Kenyan hospitals
are unable to perform routine pulse oximetry [19]. In line with
the pragmatic design of the study, we therefore included children
without signs of very severe pneumonia but with a “spot” oxygen
saturation on admission examination as low as 85% with no ev-
idence of resultant harm. The presence of wheeze was found to
have a protective association with treatment failure, a ﬁnding that
is consistent with work previously conducted in South Africa to
develop a clinical predictive score for mortality in children with
lower respiratory tract infection [20].
Randomized controlled trials are frequently criticized for
their lack of external validity [21] due to strict eligibility criteria
and differences between trial protocols and routine care. To en-
sure that the trial was conducted under conditions representa-
tive of typical settings in district-level hospitals across Africa
with large patient volumes and diverse clinical presentations,
we adopted a pragmatic design. Whereas 1 study clinician per
site reviewed trial patients, daily further clinical and nursing
Table 3. Day of Occurrence and Reasons for Treatment Failure
Reason for Treatment Failure
Day Postenrollment Total
1 2 3 4 5 Amoxicillin Benzyl Penicillin All
Signs of very severe pneumonia 17 11 4 (1a) 1 0 18 15 33
Persisting distress 0 4 0 0 0 2 2 4
Clinician’s decision 1 2 3 3 2 7 4 11
Change of diagnosis 5 0 3 1 0 1 8 9
Withdrawal of consent 1 0 1 0 0 1 1 2
Total 24 17 11 5 2 29 30 59
a Death following treatment failure.
Figure 5. Outcome of recruited patients on day 14 postenrollment.
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management was undertaken by hospital staff with access to
routinely available resources only and with care supervised by
the hospital pediatrician. The ability to provide policy makers
data on outcomes of treatment in typical settings where chil-
dren often have comorbid conditions as well as information
on the comparative effectiveness of treatments was thought to
be critical at the outset given the prior rejection of suggested
policy changes despite moderate quality trial data [10]. The re-
sults of this trial therefore provide much-needed evidence for
pneumonia guideline development discussions in Kenya and
the sub-Saharan Africa region. Overall mortality was compara-
ble to that reported in the APPIS trial, a multicountry trial that
included children with human immunodeﬁciency virus, in
which 0.7% of participants died. Mortality in other cohorts of
children with severe pneumonia is low, ranging from 0% to
0.2% [5, 18, 22, 23]. More than half of those who failed treatment
were observed to have developed signs of very severe pneumo-
nia (6.2% of enrolled children) requiring broad-spectrum par-
enteral antibiotics and, in many cases, oxygen. The challenge of
determining the contribution of these more aggressive treat-
ment options to the patients’ ultimate clinical outcome if chil-
dren are treated from the outset as outpatients, as now
recommended by WHO, will warrant consideration as coun-
tries develop contextually appropriate policies.
Negative views regarding the efﬁcacy of oral vs injectable med-
ication may have inﬂuenced decisions to declare treatment failure
among children treated with amoxicillin more readily than in
those receiving benzyl penicillin in this open-label study. Howev-
er, misclassiﬁcation of this nature is not expected to have had an
effect on the results of the study, as it would bias the results in
favor of the standard treatment, benzyl penicillin.
CONCLUSIONS
Oral treatment of severe pneumonia offers several potential
beneﬁts including the alternative of outpatient treatment, re-
duced demand for nursing care, elimination of the risks associ-
ated with injectable medications, and a potential reduction in
the overall cost of treatment. The ﬁndings of this study are con-
sistent with those of previous trials suggesting similar outcomes
for severe pneumonia treated with benzyl penicillin and oral
amoxicillin. The pragmatic nature of the study and associated
data on the frequency and nature of treatment failure will pro-
vide important new evidence to support discussions on appro-
priate guidance for Kenya and, potentially, other countries with
similar patient populations and health systems.
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